Skip to main content
OpenTrials

Clinical trial condition

Focal Segmental Glomerulosclerosis

Explore clinical trials studying Focal Segmental Glomerulosclerosis. Study availability and eligibility vary by location and protocol.

42 public trials 16 recruiting studies
Refine in advanced search Browse all conditions

Focal Segmental Glomerulosclerosis trial results

Recruiting

Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children

NCT02235857

Conditions
Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, +11 more
Locations
  • Loma Linda University Children's Hospital Loma Linda, California, United States
  • Cedars Sinai Medical Center Los Angeles, California, United States
  • Nemours/A.I. duPont Hospital for Children Wilmington, Delaware, United States
  • Nemours Children's Health Orlando, Florida, United States
View Trial Details
Recruiting

Post Approval Study for Treatment of Drug-resistant Adult and Pediatric Primary FSGS Using the LIPOSORBER® LA-15 System

NCT04065438

Conditions
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Focal Segmental Glomerulosclerosis, +7 more
Locations
  • Loma Linda University Children's Hospital Loma Linda, California, United States
  • Loma Linda University Hospital Loma Linda, California, United States
  • Nemours/Alfred I DuPont Hospital for Children Wilmington, Delaware, United States
  • Helen DeVos Children's Hospital Grand Rapids, Michigan, United States
View Trial Details
Recruiting

ARREST-NEPHROSIS - Austrian Resistant Nephrotic Syndrome Treatment Response Registry and Biobank

NCT06162546

Conditions
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Focal Segmental Glomerulosclerosis, +15 more
Locations
  • Division of Pediatric Nephrology and Gastroenterology, Department of Pediatrics and Adolescent Medicine, Comprehensive Center for Pediatrics, Medical University of Vienna, 1090 Vienna, Austria. Vienna, Austria
View Trial Details
Recruiting

KOrea Renal Biobank NEtwoRk System TOward NExt-generation Analysis

NCT03929887

Conditions
Autoimmune Diseases, Connective Tissue Diseases, Crescentic Glomerulonephritis, +22 more
Locations
  • KangWon National University Hospital Chuncheon, South Korea
  • Keimyung University Dongsan Medical Center Daegu, South Korea
  • Chung-Ang University Hosptial Seoul, South Korea
  • Seoul National University Hospital Seoul, South Korea
View Trial Details
Completed

Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS)

NCT03493685

Conditions
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Focal Segmental Glomerulosclerosis, +7 more
Locations
  • Travere Investigational Site Mesa, Arizona, United States
  • Travere Investigational Site Phoenix, Arizona, United States
  • Travere Investigational Site Los Angeles, California, United States
  • Travere Investigational Site Northridge, California, United States
View all 226 locations
View Trial Details
Completed

Study to Evaluate R3R01 in Patients With Alport Syndrome and Patients With Focal Segmental Glomerulosclerosis

NCT05267262

Conditions
Alport Syndrome, Collagen Diseases, Congenital Abnormalities, +15 more
Locations
  • Investigative Site Los Angeles, California, United States
  • Investigative site Boca Raton, Florida, United States
  • Investigative site Miami, Florida, United States
  • Investigative site Riverview, Florida, United States
View all 22 locations
View Trial Details
Completed

PRI-VENT FSGS: Preemptive Rituximab to Prevent Recurrent Focal Segmental Glomerulosclerosis Post-Transplant

NCT03763643

Conditions
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Focal Segmental Glomerulosclerosis, +7 more
Locations
  • University of Alabama Tuscaloosa, Alabama, United States
  • University of California at Davis Davis, California, United States
  • Lurie Children's Hospital Chicago, Illinois, United States
  • University of Iowa Iowa City, Iowa, United States
View Trial Details

Related conditions